ABBV — AbbVie Inc. (Stock)

Price: $276.47 · 1 day: +1.49% · 5 days: +5.19% · 1 month: +10.19% · YTD: +21.00%
As of 2026-10-09 20:01 UTC.

52-week range: $190.75 – $277.6 (currently at 99% of the range).

The read

ABBV is in an uptrend, momentum firm. $300 is the level overhead; $275 the first support below.

6 of 6 technical checks lean bullish.

• Price vs 50-day: above
• Price vs 200-day: above
• 50d vs 200d avg: above
• MACD: bullish
• RSI momentum: 73
• 5-day tape: +5.2%

Key levels

Indicators

Next earnings: 2026-10-30.

Latest ABBV news

• AbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLC — AbbVie announced that the FDA granted two Breakthrough Therapy Designations (BTDs) for telisotuzumab adizutecan (Temab-A), bringing the company's total ADC portfolio BTDs to four. The first designation covers Temab-A in (PR Newswire, 2026-10-07)
• Halozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda SC in Multiple European Markets — A Dutch court has ruled that Merck infringed Halozyme's MDASE patent EP 2,797,622 and issued an injunction prohibiting MSD BV from manufacturing and distributing Keytruda SC in eight European markets: Belgium, Denmark, F (PR Newswire, 2026-10-07)
• Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx to Support the Development of Subcutaneous Formulations for Two Additional Exclusive Targets Using its ENHANZE® Technology — Halozyme Therapeutics announced an expansion of its collaboration agreement with argenx, increasing argenx's exclusive access to ENHANZE technology from six to eight therapeutic targets. Under the expanded deal, Halozyme (PR Newswire, 2026-10-06)
• North American Morning Briefing: Stock Futures Rise as Tech Rally Storms Ahead — Stock futures rose Tuesday as the tech rally continued, with the Nasdaq reaching a fresh record high. AI-linked earnings growth is providing support for risk appetite, according to Tickmill Group. Treasury yields eased a (Morningstar, 2026-10-06)
• AbbVie Inc. — Form 8-K: 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits — AbbVie Inc. filed a Form 8-K with the SEC on October 5, 2026, covering Items 2.02 (Results of Operations and Financial Condition) and 9.01 (Financial Statements and Exhibits). The filing serves as the company's official (SEC EDGAR, 2026-10-05)
• There's one pharma-linked stock most investors have never heard of. It's on Josh Brown's list — West Pharmaceutical Services (WST) manufactures injectable drug packaging components including rubber stoppers, seals, and auto-injectors for pharmaceutical and biotech companies. After a severe 38% single-day decline in (CNBC, 2026-10-01)
• Halozyme Announces Appointment of Jim Daly to its Board of Directors — Halozyme Therapeutics announced the appointment of James Daly to its Board of Directors on September 30, 2026. Daly is a biopharmaceutical executive with over three decades of commercial leadership experience, previously (PR Newswire, 2026-09-30)
• Piramal Pharma Solutions and NP2 to Complete Cyclophosphamide Development Phase Next Month — Piramal Pharma Solutions (PPS) and nonprofit generic drug manufacturer NP2 announced plans to complete the drug development phase of the generic cancer drug cyclophosphamide in October, with manufacturing to occur at PPS (PR Newswire, 2026-09-30)

Explore more

Interactive ABBV chart and analyst chat · Market terminal — movers, signals and news · Use MarketCrew inside Claude · Use MarketCrew inside ChatGPT · Top gainers today · 52-week highs